Prospective comparison of subcutaneous vs intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and

被引：0
|
作者：
Moreau, P.
Coiteux, V.
Hulin, C.
Facon, T.
van de Velde, H.
Acharya, M.
Harousseau, J. L.
机构：
[1] Univ Hosp Nantes, Dept Hematol, Nantes, France
[2] Johnson & Johnson Pharmaceut R&D, Beerse, Belgium
[3] Johnson & Johnson Pharmaceut R&D, Raritan, NJ USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [21] Dermatosis toxica and phlebitis - adverse effects in a patient with multiple myeloma after bortezomib administration subcutaneous and intravenous
    Piribauer, M.
    Tomka, M.
    Weiss, H.
    Siebert, F.
    Oncology Research and Treatment, 2015, 38 : 240 - 241
  • [22] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Tomohiko Kamimura
    Toshihiro Miyamoto
    Shuichiro Takashima
    Noriko Yokota
    Yong Chong
    Yoshikiyo Ito
    Koichi Akashi
    International Journal of Hematology, 2012, 96 : 525 - 527
  • [23] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Kamimura, Tomohiko
    Miyamoto, Toshihiro
    Takashima, Shuichiro
    Yokota, Noriko
    Chong, Yong
    Ito, Yoshikiyo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (04) : 525 - 527
  • [24] Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
    Xu, Yan
    Deng, Shuhui
    Mao, Xuehan
    An, Gang
    Li, Zengjun
    Wang, Yafei
    Fulciniti, Mariateresa
    Ho, Matthew
    Lin, Jianhong
    Sui, Weiwei
    Liu, Wei
    Zou, Dehui
    Yi, Shuhua
    Huang, Wenyang
    Liu, Hong
    Lv, Rui
    Li, Jian
    Wang, Tingyu
    Du, Chenxing
    Munshi, Nikhil C.
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (06): : 422 - 430
  • [25] Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    Moreau, Philippe
    Pylypenko, Halyna
    Grosicki, Sebastian
    Karamanesht, Ievgenii
    Leleu, Xavier
    Grishunina, Maria
    Rekhtman, Grigoriy
    Masliak, Zvenyslava
    Robak, Tadeusz
    Shubina, Anna
    Arnulf, Bertrand
    Kropff, Martin
    Cavet, James
    Esseltine, Dixie-Lee
    Feng, Huaibao
    Girgis, Suzette
    van de Velde, Helgi
    Deraedt, William
    Harousseau, Jean-Luc
    LANCET ONCOLOGY, 2011, 12 (05): : 431 - 440
  • [26] Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits
    Petrucci, Maria Teresa
    Finsinger, Paola
    Chisini, Marta
    Gentilini, Fabiana
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 939 - 946
  • [27] A PROSPECTIVE TIME AND MOTION ANA LYSIS COMPARING INTRAVENOUS (IV) VESUS SUBCUTANEOUS (SC) BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM)
    Dranitsaris, G.
    Kaura, S.
    VALUE IN HEALTH, 2013, 16 (07) : A427 - A427
  • [28] Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma
    Podar, Klaus
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2014, 6 : 15 - 23
  • [29] INTRAVENOUS SWITCHING OF BORTEZOMIB CAN OVERCOME RESISTANCE AFTER SUBCUTANEOUS ADMINSTRATION IN MULTIPLE MYELOMA PATIENTS
    Gozzetti, A.
    Candi, V.
    Papini, G.
    Defina, M.
    Schiattone, L.
    Bocchia, M.
    HAEMATOLOGICA, 2014, 99 : 651 - 652
  • [30] Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic
    Soefje, Scott
    Carpenter, Corinne
    Carlson, Katherine
    Awasthi, Samir
    Lin, Thomas S.
    Kaila, Shuchita
    Tarjan, Daniel
    Kayal, Nikhil
    Kirkup, Christian
    Wagner, Tyler
    Gray, Kathleen
    Kumar, Shaji
    BLOOD, 2021, 138
12345